Novo shares moved lower on Monday. - Nichlas Pollier/Bloomberg News Novo Nordisk Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new blockbusters over the next few years but investors aren't yet convinced the Danish drugmaker is close to finding its next Ozempic. Novo's shares were down roughly 6% on Monday during the company's investor day in London. Most Read from The Wall Street Journal The New Ways to Thrive at Work Now, According to Adam Grant Paramount Discussed $1.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。